International HBV Meeting Program

“Molecular Biology of Hepatitis B Viruses”

Sunday, September 3 – Wednesday, September 6, 2017

 

Preliminary Program

Sunday, September 3, 2017       

1 p.m. - Meeting Registration Opens 

6 p.m. - Opening Evening Cheese & Wine Reception & Poster Session I

 

Monday, September 4, 2017       

Keynote Lecture I:   Hepatitis A Virus (Stanley Lemon, UNC)

Session I – Viral Entry and New Models

Session II – cccDNA and Transcription

Session III – Reverse Transcription and Morphogenesis

Poster Session II

 

Tuesday, September 5, 2017     

Keynote Lecture II:    Hepatitis E Virus (Xiang-Jin Meng, Virginia Tech)

Session IV – Innate Immune Response

Session V – Adaptive Immune Response

Session VI – Viral Pathogenesis

Session VII – Genotypes and Variants

Poster Session III

 

Wednesday, September 6, 2017

Keynote Lecture III:  RNA Biology & Viral Infection (Bryan Cullen, Duke)

Session VIII – Regulatory Proteins                   

Session IX – Hepatocellular Carcinoma

Session X – Antiviral Therapy

Banquet at the National Zoo, Washington, DC
Presentation of the inaugural Distinguished Award in Hepatitis B Research to Dr. Francis Chisari

 

Thursday, September 7, 2017 - Satellite Symposium

8:30 am – 1 pm   Novel HBV Antiviral and Immune Modulatory Therapies in Preclinical/ Clinical Development

Chairs:  Anna Lok and Marc Ghany 
(please see below for additional information)

Banquet at the Zoo on Wednesday, September 6

This year's banquet will be held the evening of Wednesday, September 6 at the Smithsonian’s National Zoo, part of the Smithsonian Institution, the world’s largest museum and research complex. Founded in 1889, the Zoo sits on 163 acres in the heart of Washington, D.C.’s Rock Creek Park and is home to more than 1,500 animals across 300 different species. The zoo is just a short walk from the Omni Shoreham Hotel.  Please visit www.nationalzoo.si.edu for more information.

 

Satellite Symposium

"New HBV Antiviral and Immune Modulatory Therapies in Late Pre-Clinical/Clinical Development"

Anna Lok, Univ. of Michigan and Marc Ghany, NIH, Program Chairs

Thursday, September 7, 8:30 AM – 1:00 PM

Description of Symposium: There has been a resurgence in interest in therapy of chronic hepatitis B with the development of novel inhibitors of HBV life cycle and therapies aimed at restoring host immune response to HBV. This symposium will provide an overview of gaps in knowledge of current and future HBV treatment, as well as discussion on endpoints and designs of clinical trials aimed at HBV cure.

Attendees will have a greater understanding of the current status of drug development for chronic HBV infection and the appropriate endpoints to guide early and late phase drug development and they will be aware of the appropriate populations to study novel agents with different mechanisms of action.

Target Audience: Hepatologists, Academic Researchers (basic and clinical), Pharmaceutical and Biotechnology Drug Developers and Regulatory agencies 

 

Preliminary Program

Introductory remarks - Jake Liang, Marc Ghany, Anna Lok

Session I
1. Current HBV treatment: efficacy and limitations
Marc G Ghany

2. HBV lifecycle and potential targets for antiviral therapy
Fabien Zoulim

3. Immune response to HBV and strategies to restore immune response
Adam Gehring

4. Definition of HBV cure and pathway to regulatory approval
Anna SF Lok

5. Panel discussion
Speakers + FDA

Session II – abstract presentations
8-10 abstracts: 8 min oral presentations + 4 min discussion

Closing remarks - Jake Liang, Marc Ghany, Anna Lok

 

If any pharmaceutical and biotech companies are interested in presenting their anti-HBV drugs in late preclinical and clinical pipeline in this Satellite Symposium, please contact info@hbvmeeting.org.

For information on submitting abstracts for either the regular meeting or the Satellite Symposium click here.